insulin secretagogues

Description Results NMA

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

HbA1c goal <7% 2.40 [1.55; 3.70]

all hypoglycemia 0.00 [0.00; NaN]

all cause deaths 0.88 [0.71; 1.08]

CV deaths 0.80 [0.60; 1.05]

stroke 0.90 [0.55; 1.48]

MI 1.07 [0.88; 1.31]

CV events 0.96 [0.83; 1.11]

alogliptin 12.5 and 25 mg once daily (n=210)

vs.

placebo (n=104)

double-blind

Parallel groups

Sample size: 210/104

Primary endpoint:

FU duration: 26 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin and gliclazide (n=-9)

vs.

metformin and rosiglitazone (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

gliclazide plus metformin (n=-9)

vs.

nateglinide plus metformin (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

gliclazide 80 mg o.d. (titrated up to 320 mg (n=313)

vs.

pioglitazone 15 mg o.d. (titrated up to 45 mg (n=317)

double-blind

Sample size: 313/317

Primary endpoint:

FU duration: 52 weeks

glimepiride monotherapy (n=-9)

vs.

metformin monotherapy (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 20 weeks

glimepiride (4 mg once daily). (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 26 weeks

CV death 1.00 [0.38; 2.62]

All-cause mortality 1.00 [0.38; 2.62]

Stroke 1.00 [0.38; 2.62]

Myocardial infarction 1.00 [0.38; 2.62]

glimepiride, 1, 4, or 8 mg once daily (n=304)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 304/0

Primary endpoint:

FU duration: 14 weeks

glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks (n=123)

vs.

placebo (n=126)

double-blind

Parallel groups

Sample size: 123/126

Primary endpoint:

FU duration:

glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d (n=416)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 416/0

Primary endpoint:

FU duration: 14 weeks

glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: change in HbA(1c)

FU duration: 14 weeks

metformin and glimepiride (n=-9)

vs.

metformin (n=-9)

metformin, glimepiride or metformin and glimepiride

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

glimepiride 0.25mg od, 0.5mg od (n=62)

vs.

placebo (n=31)

Sample size: 62/31

Primary endpoint:

FU duration:

glimepiride 1-8mg od (n=122)

vs.

placebo (n=125)

Sample size: 122/125

Primary endpoint:

FU duration:

Glimepiride (16 mg/day) plus insulin (n=72)

vs.

insulin plus placebo (n=73)

Sample size: 72/73

Primary endpoint:

FU duration:

glimepiride 1-4mg od (n=96)

vs.

gliclazide 80-320 mg/day (od or bid) (n=107)

Sample size: 96/107

Primary endpoint:

FU duration:

glimepiride 1 mg daily (n=524)

vs.

2.5 mg glibenclamide (n=520)

double-blind

Parallel groups

Sample size: 524/520

Primary endpoint: not unique

FU duration:

glimepiride 1-16mg od (n=289)

vs.

non-micronized glyburide 1.25-20mg od (n=288)

double-blind

Parallel groups

Sample size: 289/288

Primary endpoint:

FU duration:

glimepiride (n=172)

vs.

gliclazide or glibenclamide (n=0)

open

Parallel groups

Sample size: 172/0

Primary endpoint:

FU duration: 6 months

glimepiride 1-8mg od (n=427)

vs.

glibenclamide 1.75-14 mg/day (od or bid) (n=425)

Sample size: 427/425

Primary endpoint:

FU duration:

glimepiride 1-16 mg/day (od or bid) (n=444)

vs.

glipizide 2.5-40 mg/day (od or bid) (n=208)

Sample size: 444/208

Primary endpoint:

FU duration:

glimepirid e6mg od (n=50)

vs.

glimepiride 3mg bid (n=48)

Cross over

Sample size: 50/48

Primary endpoint:

FU duration:

glipizide (n=-9)

vs.

sitagliptin (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

2.5 mg glipizide GITS (n=61)

vs.

placebo (n=61)

double-blind

Sample size: 61/61

Primary endpoint:

FU duration: 16 weeks

glipizide, 2.5 or 5 mg/day (n=139)

vs.

glyburide, 1.25 or 2.5 mg/day (n=0)

open

Parallel groups

Sample size: 139/0

Primary endpoint:

FU duration: 4 months

glipizide (n=-9)

vs.

glyburide (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

glipizide (n=-9)

vs.

glyburide (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 15 months

once-daily doses of 5, 20, 40, or 60 mg glipizide GITS (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 4+8 weeks

5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377)

vs.

placebo (n=192)

Parallel groups

Sample size: 377/192

Primary endpoint:

FU duration: 12 weeks

glipizide/metformin 5/500 mg tablets (n=-9)

vs.

metformin 500-mg (n=-9)

glipizide 30-mg, metformin 500-mg, or glipizide/metformin 5/500 mg

open

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg) (n=-9)

vs.

metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment) (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

glyburide 2.5 mg (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

glibenclamide (2.5 mg X 3/d) (n=-9)

vs.

placebo (n=-9)

double-blind

Factorial plan

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin + glibenclamide (n=-9)

vs.

metformin (n=-9)

metformin, glibenclamide or the combination of both

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 6 months

metformin and glyburide (n=-9)

vs.

metformin (n=-9)

metformin and glyburide vs. metformin vs. glyburide

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 29 weeks

low-dose glyburide plus metformin (n=-9)

vs.

high-dose glyburide alone (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) < or = 7 mmol/l (n=-9)

vs.

metformin 500 mg, (n=-9)

metformin 500 mg, glibenclamide 5 mg, metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) (n=-9)

vs.

metformin 500 mg (n=-9)

glyburide 10 mg b.i.d. (n = 164); metformin 500 mg (n = 153); glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d (n=-9)

vs.

metformin (500 to 3,000 mg/d), (n=-9)

metformin (500 to 3,000 mg/d), glibenclamide (5 to 15 mg/d), or their combination (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d

double-blind

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration: 6 months

glyburide/metformin (n=-9)

vs.

metformin (n=-9)

glyburide/metformin tablets vs. metformin or glyburide monotherapy

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

linagliptin (n=-9)

vs.

combination of metformin and an SU (n=-9)

Sample size: -9/-9

Primary endpoint: change from baseline in HbA1c

FU duration: 24 weeks

Linagliptin (1, 5, or 10 mg taken once daily) (n=-9)

vs.

placebo (on top Metformin ) (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

linagliptin 5 mg once daily (n=524)

vs.

placebo add on MET (n=177)

Sample size: 524/177

Primary endpoint:

FU duration:

linagliptin 5 mg (n=-9)

vs.

placebo (add-on to sulphonylurea) (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint: change from baseline HbA1c

FU duration: 18 weeks

Linagliptin monotherapy (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint: change from baseline in HbA1c

FU duration: 24 weeks

initial combination of 30 mg pioglitazone plus 5 mg linagliptin (n=-9)

vs.

pioglitazone plus placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

CV events 0.46 [0.23; 0.91]

CVdeath 1.00 [0.14; 7.14]

linagliptin (n=776)

vs.

glimepiride 1-4 mg QD (n=775)

double-blind

Sample size: 776/775

Primary endpoint: change in HbA1c

FU duration: 2 years

linagliptin (5 mg once daily) add-on therapy to preferably > 1500 mg metformin (n=777)

vs.

glimepiride (1—4 mg) orally once daily add-on therapy to preferably > 1500 mg metformin (n=775)

double-blind

Parallel groups

Sample size: 777/775

Primary endpoint: change from baseline in HbA1c

FU duration: 104 weeks

mitiglinide 10 - 20 mg three times daily (n=291)

vs.

nateglinide 120 mg three times daily (n=0)

double-blind

Parallel groups

Sample size: 291/0

Primary endpoint:

FU duration: 20 weeks

additional mitiglinide 5 or 10 mg tid (n=-9)

vs.

placebo on top pioglitazone (n=-9)

multicenter

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

mitiglinide (n=-9)

vs.

on top of once daily insulin glargine (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Nateglinide (n=-9)

vs.

repaglinide (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

nateglinide 90 mg three times daily (n=115)

vs.

repaglinide 1.0 mg three times daily (n=115)

Parallel groups

Sample size: 115/115

Primary endpoint:

FU duration: 12 weeks

nateglinide 60 mg, 120 mg before three meals (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

120 mg nateglinide before meals (n=179)

vs.

placebo (n=172)

double-blind

Parallel groups

Sample size: 179/172

Primary endpoint:

FU duration:

nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg (n=229)

vs.

placebo (n=60)

double-blind

Parallel groups

Sample size: 229/60

Primary endpoint:

FU duration: 12 weeks

nateglinide (30, 60, or 120 mg, with meals). (n=675)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 675/0

Primary endpoint:

FU duration: 24 weeks

30, 60, or 120 mg nateglinide (n=108)

vs.

placebo (n=0)

double_blind

Parallel groups

Sample size: 108/0

Primary endpoint:

FU duration: 24 weeks

repaglinide (n=66)

vs.

placebo (n=33)

double-blind

Parallel groups

Sample size: 66/33

Primary endpoint:

FU duration:

repaglinide 1 mg or repaglinide 4 mg (n=286)

vs.

placebo (n=75)

double-blind

Parallel groups

Sample size: 286/75

Primary endpoint:

FU duration: 24 weeks

repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. (n=253)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 253/0

Primary endpoint:

FU duration: 16 weeks

0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response) (n=408)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 408/0

Primary endpoint:

FU duration: 16 weeks

nateglinide plus metformin (n=133)

vs.

gliclazide plus metformin (n=129)

double-blind

Parallel groups

Sample size: 133/129

Primary endpoint:

FU duration: 24 weeks

repaglinide 2 mg thrice daily (n=-9)

vs.

metformin 1 g twice daily (n=-9)

double-blind

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide, administered preprandially three times daily (n=-9)

vs.

glibenclamide, given preprandially once or twice daily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 14 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide (0.5-4 mg t.i.d.) (n=211)

vs.

glyburide (1.75-10.5 mg daily) (n=109)

double-blind

Sample size: 211/109

Primary endpoint:

FU duration: 1 year

repaglinide, 1-4 mg at mealtimes (n=256)

vs.

glipizide, 5-15 mg daily (n=0)

double-blind

Sample size: 256/0

Primary endpoint:

FU duration: 1 year

repaglinide (0.5–4.0 mg at meals), (n=256)

vs.

combination of repaglinide (1–4 mg at meals) and troglitazone (200–600 mg once daily) (n=0)

open

Sample size: 256/0

Primary endpoint:

FU duration: 22 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

prestudy dose of metformin with the addition of repaglinide (n=27)

vs.

prestudy dose of metformin (n=27)

open

Parallel groups

Sample size: 27/27

Primary endpoint:

FU duration: 12 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide (n=66)

vs.

placebo (n=33)

double-blind

Parallel groups

Sample size: 66/33

Primary endpoint:

FU duration: 18 weeks

repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) (n=286)

vs.

placebo (n=75)

double-blind

Sample size: 286/75

Primary endpoint:

FU duration: 24 weeks

saxagliptin added to a submaximal sulphonylurea dose (n=-9)

vs.

uptitration of sulphonylurea monotherapy (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Saxagliptin in Combination With Metformin XR 1500 mg (n=-9)

vs.

Up-titrated Metformin XR to 2000 mg (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

HbA1c goal <7% 2.63 [1.81; 3.81]

all hypoglycemia 0.94 [0.06; 14.87]

HbA1c goal <7% 1.32 [1.25; 1.39]

all hypoglycemia 1.22 [0.82; 1.83]

nephropathy 1.08 [0.88; 1.32]

all cause deaths 1.10 [0.96; 1.26]

CV deaths 1.03 [0.87; 1.21]

stroke 1.10 [0.88; 1.38]

MI 0.95 [0.80; 1.12]

CV events 1.00 [0.90; 1.11]

saxagliptin (2.5, 5, or 10 mg once daily) (n=191)

vs.

placebo (n=179)

Sample size: 191/179

Primary endpoint:

FU duration: 24 weeks

saxagliptin (n=-9)

vs.

placebo added to patients’ current diabetes treatment (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

saxagliptin 2.5, 5, 10, 20 or 40 mg once daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

oral saxagliptin 2.5, 5, or 10 mg once daily (n=-9)

vs.

placebo (n=-9)

treatment-naïve patients with type 2 diabetes

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

Saxagliptin monotherapy (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

saxagliptin (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Saxagliptin, 5 mg (n=-9)

vs.

placebo (on top insulin) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Saxagliptin (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

2.5 mg Saxagliptin, Twice Daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

saxagliptin (2.5 or 5 mg) (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Saxagliptin (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Saxagliptin 5 mg or 2.5 mg once daily (n=16500)

vs.

Placebo (n=0)

Parallel groups

Sample size: 16500/0

Primary endpoint: cardiovascular death, MI, ischaemic stroke,

FU duration:

saxagliptin (n=-9)

vs.

titrated glipizide plus metformin (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

saxagliptin 5 mg once daily add on metformin (n=403)

vs.

sitagliptin 100 mg onece daily add on metformin (n=398)

Parallel groups

Sample size: 403/398

Primary endpoint:

FU duration: 18 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin/metformin 50/500 mg bid uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid (n=-9)

vs.

metformin monotherapy (n=-9)

NA

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin phosphate, 100 mg daily (n=-9)

vs.

rosiglitazone maleate, 4 mg daily (n=-9)

open

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

sitagliptin 50 mg once daily monotherapy (n=-9)

vs.

voglibose 0.2 mg thrice daily before meals (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

Adverse events leading to treatment discontinuation 0.96 [0.40; 2.31]

Adverse events leading to treatment discontinuation 0.74 [0.32; 1.71]

Adverse events leading to treatment discontinuation 1.01 [0.39; 2.59]

Adverse events leading to treatment discontinuation 0.00 [0.00; NaN]

Adverse events leading to treatment discontinuation 0.00 [0.00; NaN]

Adverse events leading to treatment discontinuation 3.07 [0.32; 29.15]

Adverse events leading to treatment discontinuation 1.34 [0.60; 2.98]

Adverse events leading to treatment discontinuation 2.74 [0.29; 25.95]

Adverse events leading to treatment discontinuation 0.76 [0.40; 1.44]

Adverse events leading to treatment discontinuation 5.59 [1.26; 24.88]

Adverse events leading to treatment discontinuation 3.87 [0.44; 33.99]

sitagliptin 100 or 200 mg dailym (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

sitagliptin 100 mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 25 mg or 50 mg or 100 mg dailyi (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily monotherapy (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg (or 200 mg) daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50 mg b.i.d (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on tometformin therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin)ocumen (n=-9)

vs.

placebo (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on to metformin therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to pioglitazone therapy)sl˜ðõØ (n=-9)

vs.

placebo (add-on to pioglitazone therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on to metformin therapy). (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

once-daily sitagliptin (100 or 50 mg, depending on renal function) (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

once-daily sitagliptin 100 mg (n=322)

vs.

placebo (n=319)

double-blind

Sample size: 322/319

Primary endpoint:

FU duration:

sitagliptin 100mg once daily monotherapy (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 18 weeks

sitagliptin (n=65)

vs.

placebo (n=26)

double-blind

Sample size: 65/26

Primary endpoint:

FU duration: 12 weeks

sitagliptin 100 mg once daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg once daily (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

sitagliptin 100 dailyily (n=-9)

vs.

metformin 1000 mg or 2000 mg daily;imag (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50 mg daily plus metformin 1000 or 2000 mg dailyç$4 (n=-9)

vs.

metformin 1000 or 2000 mg daily (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

once-daily sitagliptin 100 mg (n=528)

vs.

twice-daily metformin 1000 mg (n=522)

double-blind

Sample size: 528/522

Primary endpoint:

FU duration: 24 weeks

pioglitazone 30 mg plus sitagliptin 100 mg once a day (n=-9)

vs.

pioglitazone 15 mg plus metformin 850 mg twice a day (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50mg bid (n=-9)

vs.

glipizide 5mg to 20 mg dailyitm (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

sitagliptin 100 mg qd (n=507)

vs.

prestudy sulphonylurea (n=514)

open

Parallel groups

Sample size: 507/514

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (n=516)

vs.

glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day) (n=519)

double-blind

Parallel groups

Sample size: 516/519

Primary endpoint:

FU duration: 30 weeks

sitagliptin100 mg qd (n=-9)

vs.

pioglitazone 15 mg qd, up-titrated to 30 mg after 6 weeks (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

vildagliptin (50 mg given once or twice daily) (n=515)

vs.

placebo (n=0)

double-blind

Sample size: 515/0

Primary endpoint:

FU duration: 24 weeks

vildagliptin (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg daily, given as 50 mg twice daily (n=441)

vs.

acarbose (up to 300 mg daily, given as three equally divided doses (n=220)

double-blind

Sample size: 441/220

Primary endpoint:

FU duration: 24 weeks

Vildagliptin 50 mg Bid (n=-9)

vs.

Voglibose 0.2 mg Tid (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

vildagliptin (50 mg bid, (n=188)

vs.

voglibose (0.2 mg tid (n=192)

double-blind

Sample size: 188/192

Primary endpoint:

FU duration: 12 weeks

Adverse events leading to treatment discontinuation 1.01 [0.33; 3.07]

Adverse events leading to treatment discontinuation 4.38 [1.29; 14.86]

Adverse events leading to treatment discontinuation ∞ [NaN; ∞]

Adverse events leading to treatment discontinuation 0.60 [0.10; 3.47]

Adverse events leading to treatment discontinuation 2.24 [0.89; 5.68]

Adverse events leading to treatment discontinuation NaN [NaN; NaN]

Adverse events leading to treatment discontinuation 1.73 [0.52; 5.81]

Adverse events leading to treatment discontinuation 9.50 [1.22; 74.05]

Adverse events leading to treatment discontinuation 1.25 [0.34; 4.57]

all hypoglycemia ∞ [NaN; ∞]

vildagliptin 50 mg or 100 mg daily (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 20 mg or 50 mg or 100 mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50 mg or 100 mg daily, imag (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 25mg bid (n=70)

vs.

placebo (n=28)

double-blind

Sample size: 70/28

Primary endpoint:

FU duration:

vildagliptin 25mg or 50mg or 100mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50 mg qd (n=156)

vs.

placebo (n=150)

double-blind

Parallel groups

Sample size: 156/150

Primary endpoint:

FU duration: 52 weeks

vildagliptin 50 mg daily (add-on to metformin therapy)j (n=56)

vs.

placebo (add-on to metformin therapy)mag (n=51)

double-blind

Sample size: 56/51

Primary endpoint:

FU duration: 12 weeks

vildagliptin (50 or) 100 mg daily (add-on to metformin therapy)m (n=185)

vs.

placebo (add-on to metformin therapy)mag (n=182)

double-blind

Sample size: 185/182

Primary endpoint:

FU duration:

vildagliptin 100 mg daily (add-on to insulin therapy)y) (n=144)

vs.

placebo (add-on to insulin therapy)y)mag (n=152)

double-blind

Sample size: 144/152

Primary endpoint:

FU duration: 24 weeks

vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy) (n=463)

vs.

placebo (add-on to pioglitazone therapy) (n=0)

Sample size: 463/0

Primary endpoint:

FU duration:

ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening (n=125)

vs.

placebo (n=122)

double-blind

Parallel groups

Sample size: 125/122

Primary endpoint:

FU duration: 24 weeks

vildagliptin (50 mg q.d.) (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily), (n=1179)

vs.

high-dose metformin monotherapy (1000 mg twice daily). (n=0)

Sample size: 1179/0

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg (n=29)

vs.

placebo (n=30)

Sample size: 29/30

Primary endpoint:

FU duration:

vildagliptin 50mg bid (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Vildagliptin and Metformin (25/1000 mg Bid) (n=-9)

vs.

Metformin Monotherapy (1000 mg Bid) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50mg twice-daily (n=102)

vs.

placebo (n=100)

double-blind

Sample size: 102/100

Primary endpoint:

FU duration: 12 weeks

Vildagliptin 50 mg Bid or qd (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 50mg qd, 50mg bid or 100mg qd (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

Vildagliptin 100 mg o.d. (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg/d) (n=-9)

vs.

placebo (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (n=-9)

vs.

placebo (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (50 mg qd) (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin added to insulin (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

all hypoglycemia 0.10 [0.07; 0.16]

HbA1c goal <7% 0.97 [0.90; 1.05]

vildagliptin 50 mg twice daily (n=1396)

vs.

glimepiride titrated up to 6 mg/day (n=1393)

double-blind

Parallel groups

Sample size: 1396/1393

Primary endpoint: HbA1c

FU duration: 52 weeks

vildagliptin (50 mg twice daily (n=513)

vs.

gliclazide (up to 320 mg/day (n=494)

double-blind

Sample size: 513/494

Primary endpoint:

FU duration: 52 weeks

monotherapy with vildagliptin 50 mg bid (n=-9)

vs.

gliclazide up to 320 mg/day (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 2 years

vildagliptin (n=-9)

vs.

glimepiride (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 2 years

Adverse events leading to treatment discontinuation 0.58 [0.30; 1.10]

vildagliptin 100mg (n=526)

vs.

metformin up to 2000 mg daily (n=254)

Sample size: 526/254

Primary endpoint:

FU duration: 52 weeks

vildagliptin (100 mg daily) (n=-9)

vs.

metformin (2 000 mg daily). (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg daily (n=169)

vs.

metformin (titrated to 1500 mg daily (n=166)

Sample size: 169/166

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Adverse events leading to treatment discontinuation 0.95 [0.38; 2.36]

Adverse events leading to treatment discontinuation 0.47 [0.15; 1.49]

vildagliptin 100 mg daily daily (n=519)

vs.

rosiglitazone 8 mg once daily (n=267)

double-blind

Sample size: 519/267

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg daily daily (n=-9)

vs.

pioglitazone 30 mg dailyaily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 100 mg daily (add-on to metformin therapy) (n=295)

vs.

pioglitazone 30 mg daily (add-on to metformin therapy)j (n=281)

double-blind

Sample size: 295/281

Primary endpoint:

FU duration:

vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone dailyi (n=-9)

vs.

pioglitazone 30 mg daily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg (n=1653)

vs.

TZD (agent and dose at the investigators' discretion (n=825)

Sample size: 1653/825

Primary endpoint:

FU duration:

vildagliptin (50 mg b.i.d (n=396)

vs.

rosiglitazone (8 mg q.d., (n=202)

double-blind

Sample size: 396/202

Primary endpoint:

FU duration: